MILLENNIUM MANAGEMENT LLC - XENON PHARMACEUTICALS INC ownership

XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 164 filers reported holding XENON PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.5%.

Quarter-by-quarter ownership
MILLENNIUM MANAGEMENT LLC ownership history of XENON PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$5,140,841
-37.4%
150,493
-29.5%
0.00%
-25.0%
Q2 2023$8,213,513
+103527.5%
213,338
-3.7%
0.00%
-20.0%
Q1 2023$7,926
-66.2%
221,470
-62.7%
0.01%
-61.5%
Q4 2022$23,443
-99.9%
594,541
+6.1%
0.01%
+8.3%
Q3 2022$20,229,000
+35.0%
560,349
+13.7%
0.01%
+33.3%
Q2 2022$14,988,000
+259.7%
492,691
+261.4%
0.01%
+350.0%
Q1 2022$4,167,000
+47.2%
136,326
+50.4%
0.00%
+100.0%
Q4 2021$2,831,000
-37.5%
90,621
-69.4%
0.00%
-50.0%
Q3 2021$4,526,000
-19.5%
296,219
-1.8%
0.00%
-33.3%
Q2 2021$5,619,000
-8.5%
301,748
-12.0%
0.00%
-25.0%
Q1 2021$6,138,000
-4.2%
342,899
-17.7%
0.00%
-20.0%
Q4 2020$6,405,000
+386.7%
416,475
+250.4%
0.01%
+150.0%
Q3 2020$1,316,000
-37.5%
118,845
-29.3%
0.00%
-33.3%
Q2 2020$2,107,000
-4.0%
167,996
-13.2%
0.00%
-40.0%
Q1 2020$2,195,000
+250.6%
193,569
+305.7%
0.01%
+400.0%
Q4 2019$626,000
+27.5%
47,714
-1.2%
0.00%0.0%
Q1 2019$491,000
-46.5%
48,286
-66.8%
0.00%0.0%
Q4 2018$917,000
-16.2%
145,382
+75.4%
0.00%0.0%
Q3 2018$1,094,000
-26.6%
82,873
-57.2%
0.00%
-66.7%
Q4 2016$1,491,000193,6740.00%
Other shareholders
XENON PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Ghost Tree Capital, LLC 850,000$15,215,0003.58%
ACUTA CAPITAL PARTNERS, LLC 412,500$7,384,0002.66%
BVF INC/IL 3,481,778$62,324,0002.34%
Soleus Capital Management, L.P. 708,117$12,675,0002.28%
COMMODORE CAPITAL LP 301,392$5,395,0002.15%
DAFNA Capital Management LLC 406,535$7,277,0001.73%
Parkman Healthcare Partners LLC 374,395$6,702,0001.56%
Avoro Capital Advisors LLC 3,650,000$65,335,0001.13%
KNOTT DAVID M 144,101$2,579,0001.10%
Orbimed Advisors 2,497,917$44,713,0000.42%
View complete list of XENON PHARMACEUTICALS INC shareholders